Condition: Relapsed or Refractory Multiple Myeloma (RRMM) · Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
The purpose of this study is to compare the efficacy and safety of arlo-cel (BMS-986393) versus standard regimens in adult participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma.
This description comes directly from the study's public registry record.
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com · 855-907-3286 · Clinical.Trials@bms.com
First line of the email MUST contain NCT # and Site #.
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham | Birmingham, Alabama, United States | Recruiting |
| UCLA Hematology/Oncology - Santa Monica | Los Angeles, California, United States | Recruiting |
| University of California, Irvine (UCI) Health - UC Irvine Medical Center | Orange, California, United States | Recruiting |
| Local Institution - 0223 | Washington D.C., District of Columbia, United States | Not Yet Recruiting |
| Baptist MD Anderson Cancer Center | Jacksonville, Florida, United States | Recruiting |
| University of Miami Hospital and Clinics, Sylvester Cancer Center | Miami, Florida, United States | Recruiting |
| Local Institution - 0228 | Orlando, Florida, United States | Withdrawn |
| Winship Cancer Institute, Emory University | Atlanta, Georgia, United States | Recruiting |
| Louisiana State University Health Sciences Shreveport | Shreveport, Louisiana, United States | Recruiting |
| Boston Medical Center | Boston, Massachusetts, United States | Recruiting |
| Local Institution - 0219 | Minneapolis, Minnesota, United States | Withdrawn |
| Weill Cornell Medical College | New York, New York, United States | Recruiting |
+ 129 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06615479